Neuralstem’s lead drug crumbles in PhII, adding to a litany of failures for depression drugs and blasting shares
Neuralstem $CUR says its Phase II study of the experimental depression drug NSI-189 — its lead therapy in the pipeline — failed to hit the primary endpoint …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
